GrantMetric / Topics / Cancer Research Grants
← All Topics
🔬TOPIC FEED

Cancer Research Grants

Federal funding for cancer research, clinical trials, and oncology programs from NIH, NCI, and DOD. Covering basic research, translational science, and prevention studies.

Active Grants: 71 // Source: Grants.gov // Updated: Daily
About This Topic

Discover and fund active federal grants targeting cancer biology, treatment, screening, and prevention.

Active Opportunities (71)

PAR-25-221 01/07/2027
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
Agency HHS-NIH11

This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increas...

Health View Details →
RFA-CA-24-026 09/28/2026
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
Agency HHS-NIH11

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The ove...

Health View Details →
PAR-25-098 01/07/2027
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
Agency HHS-NIH11

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Of...

Health View Details →
PAR-23-284 09/25/2026
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
Agency HHS-NIH11

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Re...

Health View Details →
PAR-23-287 10/14/2026
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
Agency HHS-NIH11

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to in...

Health View Details →
PAR-23-276 01/07/2027
Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)
Agency HHS-NIH11

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The ove...

Health View Details →
PAR-23-277 01/07/2027
Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
Agency HHS-NIH11

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The ove...

Health View Details →
PAR-25-103 10/25/2027
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
Agency HHS-NIH11

The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum...

Health View Details →
PAR-25-145 01/07/2028
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Agency HHS-NIH11

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to add...

Health View Details →
PAR-25-043 01/07/2028
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support ...

Health View Details →
PAR-24-306 09/07/2026
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects...

Health View Details →
PAR-25-104 10/25/2027
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
Agency HHS-NIH11

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum ...

Health View Details →
PAR-25-153 09/07/2026
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identif...

Health View Details →
PAR-25-271 11/13/2026
NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
Agency HHS-NIH11

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials o...

Health View Details →
PAR-25-248 10/08/2027
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
Agency HHS-NIH11

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research i...

Health View Details →
PAR-24-311 01/07/2028
Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

The purpose of this Notice of Funding Opportunity (NOFO) is to invite research grant applications (R01) for the developm...

Health View Details →
PAR-25-075 10/14/2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoptio...

Health View Details →
PAR-25-175 01/07/2028
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) gran...

Health View Details →
PA-25-172 01/07/2028
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
Agency HHS-NIH11

This Notice of Funding Opportunity (NOFO) encourages applications for research in cancer control and population sciences...

Health View Details →
PA-25-253 09/07/2028
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
Agency HHS-NIH11

This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) ...

Health View Details →
PAR-25-069 01/07/2027
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Agency HHS-NIH11

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the...

Health View Details →
PAR-25-167 01/07/2027
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
Agency HHS-NIH11

Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support ...

Health View Details →
PAR-25-081 01/07/2027
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Agency HHS-NIH11

Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement e...

Health View Details →
PAR-25-044 01/07/2028
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support ...

Health View Details →
PAR-25-243 01/07/2028
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basi...

Health View Details →
PAR-25-095 09/07/2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating In...

Health View Details →
PAR-25-070 01/07/2027
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Agency HHS-NIH11

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the...

Health View Details →
PAR-25-336 11/15/2027
Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" ...

Health View Details →
PAR-25-337 01/07/2028
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to t...

Health View Details →
PAR-25-299 01/07/2028
Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
Agency HHS-NIH11

This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseas...

Health View Details →
PAR-25-325 09/10/2027
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural res...

Health View Details →
PAR-25-321 01/07/2028
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
Agency HHS-NIH11

Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to e...

Health View Details →
PAR-25-346 01/07/2028
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to e...

Health View Details →
PAR-25-324 09/07/2028
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)
Agency HHS-NIH11

The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant suppor...

Health View Details →
PAR-25-338 01/07/2028
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to t...

Health View Details →
PD-23-5345 See Registry
Engineering of Biomedical Systems
Agency NSF

TheEngineering of Biomedical Systemsprogram is part of the Engineering Biology and Health cluster, which also includes: ...

Technology View Details →
PAR-23-286 10/14/2026
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
Agency HHS-NIH11

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to in...

Health View Details →
PAR-23-278 01/07/2027
Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)
Agency HHS-NIH11

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The ove...

Health View Details →
PD-23-7236 See Registry
Biophotonics
Agency NSF

TheBiophotonicsprogram is part of the Engineering Biology and Health cluster, which also includes: 1) theBiosensingprogr...

Technology View Details →
PAR-25-074 10/14/2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support t...

Health View Details →
PAR-25-096 09/07/2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating In...

Health View Details →
PAR-25-244 11/16/2027
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Agency HHS-NIH11

This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basi...

Health View Details →
PAR-24-304 10/14/2026
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assa...

Health View Details →
PAR-25-079 01/07/2027
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation ...

Health View Details →
PAR-25-444 09/25/2028
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Agency HHS-NIH11

This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support N...

Health View Details →
PAR-26-134 11/22/2028
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
Agency HHS-NIH11

The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that ...

Health View Details →
PAR-23-288 05/24/2026
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
Agency HHS-NIH11

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to in...

Health View Details →
W81XWH-22-DHAPP 09/18/2027
Department of Defense HIV/AIDS Prevention Program
Agency DOD-AMRAA

ATTENTION: This announcement will be revised regularly to incorporate country specific narratives (Attachment 1 of the a...

Defense View Details →
HT942526OCRPIIRA 10/01/2026
DoW, Ovarian Cancer, Investigator-Initiated Research Award
Agency DOD-AMRAA

Summary: The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award is intended to support high-im...

Defense View Details →
HT942526OCRPPA 10/01/2026
DoW, Ovarian Cancer, Pilot Award
Agency DOD-AMRAA

Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approac...

Defense View Details →
HT942526PRCRPCTA 10/05/2026
DoW Peer Reviewed Cancer, Clinical Trial Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports t...

Defense View Details →
HT942526PRCRPIPA 10/05/2026
DoW, Peer Reviewed Cancer, Impact Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research...

Defense View Details →
HT942526PRCRPIA 10/05/2026
DoW Peer Reviewed Cancer, Idea Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, ...

Defense View Details →
HT942526OCRPCTA 10/01/2026
DoW Ovarian Cancer, Clinical Trial Award
Agency DOD-AMRAA

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a...

Defense View Details →
HT942526OCRPOCAECI 10/01/2026
DoW, Ovarian Cancer, Ovarian Cancer Academy – Early-Career Investigator Award
Agency DOD-AMRAA

Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy provi...

Defense View Details →
HT942526LCRPIDA 09/02/2026
DoW Lung Cancer Idea Development Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptua...

Defense View Details →
HT942526BCRPTBCCA 09/30/2026
DoW Breast Cancer, Transformative Breast Cancer Consortium Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award...

Defense View Details →
HT942526BCRPEOHS 07/08/2026
DoW Breast Cancer, Era of Hope Scholar Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Era of Hope Scholar Award supports individual...

Defense View Details →
HT942526BCRPCREA 07/08/2026
DoW Breast Cancer, Clinical Research Extension Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports re...

Defense View Details →
HT942526BCRPTBCCDA 07/08/2026
DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Devel...

Defense View Details →
HT942526BCRPBTA12 07/08/2026
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promisi...

Defense View Details →
HT942526LCRPTRA 09/02/2026
DoW Lung Cancer Translational Research Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports adv...

Defense View Details →
HT942526LCRPPCOSA 09/02/2026
DoW Lung Cancer Patient-Centered Outcomes and Survivorship Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Awar...

Defense View Details →
PAR-27-073 07/05/2029
Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
Agency HHS-NIH11

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages grant applications to ...

Health View Details →
RFA-FD-26-004 06/15/2026
Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers
Agency HHS-FDA

Background The FDA Oncology Center of Excellence ( OCE ) aims to advance the development and regulation of oncology prod...

Health View Details →
HT942526OCRPOCCTAECI 10/01/2026
DoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award
Agency DOD-AMRAA

Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career...

Defense View Details →
HT942526PCARPTRPA 10/07/2026
DoW Pancreatic Cancer Research Program, Translational Research Partnership Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award...

Defense View Details →
HT942526PCARPIDA 10/07/2026
DoW Pancreatic Cancer Research Program, Idea Development Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the deve...

Defense View Details →
HT942526PCARPFPTA 10/07/2026
DoW Pancreatic Cancer Research Program, Focused Pilot Award
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the explora...

Defense View Details →
HT942526BCRPBTA3 09/30/2026
DoW Breast Cancer, Breakthrough Award Level 3
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promisi...

Defense View Details →
HT942526BCRPBTA4 09/30/2026
DoW Breast Cancer, Breakthrough Award Level 4
Agency DOD-AMRAA

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promisi...

Defense View Details →
About This Funding Category

Federal cancer research funding is anchored by the National Cancer Institute (NCI), which awards approximately $6.4 billion annually across its portfolio of basic, translational, clinical, and community-level research programs. The NCI R01 mechanism funds individual investigator-initiated projects at academic institutions and research hospitals, while P01 Program Project Grants support multi-investigator teams tackling complex cancer problems from multiple angles. For research-enabled nonprofits and community organizations, NCI's cancer control and prevention portfolio provides a distinct pathway: community health education, screening outreach, and patient navigation programs receive dedicated funding separate from laboratory research. The Department of Defense Congressionally Directed Medical Research Programs (CDMRP) adds a complementary funding layer with substantial annual appropriations for specific cancers including breast, prostate, lung, and ovarian disease. Eligible applicants span universities, NCI-designated Cancer Centers, independent research institutes, patient advocacy organizations, and community health programs — each with distinct grant mechanisms calibrated to organizational capacity.

Frequently Asked Questions

Who funds cancer research grants?
The National Cancer Institute (NCI), a division of NIH, is the largest federal funder of cancer research. The Department of Defense (DOD) also operates the Congressionally Directed Medical Research Programs (CDMRP) for specific cancers including breast, prostate, and lung cancer.
How much does NCI award in cancer grants?
NCI awards approximately $6.4 billion annually in research grants and contracts. Individual R01 research grants average $400,000–$600,000 per year for 4–5 years. Larger program project grants (P01) can reach $3–5 million per year.
Can nonprofits apply for cancer research grants?
Yes. Nonprofit research institutions, academic medical centers, and cancer-focused nonprofits are all eligible for NCI and DOD cancer grants. Community organizations can apply for cancer prevention and control grants through NCI's cancer control portfolio.
Browse More Topics

Explore all federal grant topics or return to the full intelligence feed.

All Topics → Intelligence Feed →
GrantMetric Intelligence Systems — Independent federal grant intelligence platform. Not affiliated with Grants.gov, the U.S. Department of Health & Human Services, or any government agency. Grant data is sourced from the Grants.gov API for informational purposes only; always verify opportunity details directly with the funding agency before applying. Some links on this site are affiliate links — we may earn a commission at no additional cost to you. Full Disclaimer  ·  Last Reviewed: May 2026  ·  Data Methodology